EP0015909A1 - A method of producing thrombosis-resistant surfaces - Google Patents
A method of producing thrombosis-resistant surfacesInfo
- Publication number
- EP0015909A1 EP0015909A1 EP19790900219 EP79900219A EP0015909A1 EP 0015909 A1 EP0015909 A1 EP 0015909A1 EP 19790900219 EP19790900219 EP 19790900219 EP 79900219 A EP79900219 A EP 79900219A EP 0015909 A1 EP0015909 A1 EP 0015909A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- heparin
- hirudin
- salt
- metal
- palladium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0017—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a surface active agent
Definitions
- the present invention relates to a novel method of effect ⁇ ively treating surfaces with heparin, hirudin and other anticoagulant proteins for the purpose of rendering said surfaces resistant to thrombosis.
- the method comprises the treatment of said surface with a palladium salt or a rhodium salt prior to heparising said surface.
- Heparin which is a mucopolysaccharide from D-glucoseamine and glucuronic acid with a molecular weight of about 17000, has the ability of preventing the aforementioned formation of a thrombus. It is essential that a heparinized surface is stable and that the heparin is firmly bound to the surface of the object.
- -stage method of heparinizing a surface which method, in addition to washing stages, comprises treating the surface with hexadecyl amine hydrochloride heparin, an aminesoluti t glutaraldehyde and cooking salt.
- the product is considerab better than one whose surfaces have not been treated.
- the layers produced when applying this method tend to be uneve and are also liable to be washed-off by the blood flowing thereagainst, consequently, there is a need of improving the method.
- Heparin shares this property with hirudin and other anticoagulant proteins.
- Hirudin is a protein having a molecular weight of 16000 - 1000.
- the surface to be treated may be of practically any materi whatsoever, although preferably the surface is of metal, such as a stainless steel, a plastics material, such as polyvinyl chloride, polyolefins, acryl resins and co-poly ⁇ mers thereof, silicon plastics, rubber, particularly butyl rubber, and fluorocarbon plastics.
- metal such as a stainless steel
- plastics material such as polyvinyl chloride, polyolefins, acryl resins and co-poly ⁇ mers thereof, silicon plastics, rubber, particularly butyl rubber, and fluorocarbon plastics.
- the treatment metal may be one of a number of different metals. Those metals tested in particular included palladium, rhodium, nickel, cobalt and copper. Among these metals palladium and rhodium take a particular position, owing to the fact that peptide hydrogen ionisation takes place at an optimal pH range of 3-4. The pH range in the case of nickel is 4-6, in the case of cobalt 6-8 and in the case of copper 8-10. With regard to these properties see E.W. Wilson and R.B. Martin, Inorg. Chem 9, page 528 (1970).
- the well-cleaned, and optionally etched surface is treated with a solution of a metal salt of the metal soluble in the solvent used, with a preferably pharmaceutically acceptable acid.
- a suitable solvent there can be mentioned primarily water, and water in mix ⁇ tures with a polar solvent m-iscible therewith.
- Polar organic solvents can also be used. Among those polar solvents which can be used are alkanols, such as methanol and ethanol.
- Suitable salts are primarily chlorides, sul ⁇ phates, nitrates, acetates, citrates, although it lies within the expertise of one skilled in this art to select other suitable soluble salts of the metal used.
- Rhodium can be used in the same manner.
- the treatment with the metal salt takes only some seccnds up to some minutes, depending upon the temperature of the solution and its pH, and takes place at an ion strength o 0.3-3 mmol metal salt per litre, which in the case of the mentioned palladium salts corresponds to 0.1-0.5 grams of salt per litre.
- the temperature may be room temperature, although a temperature of 50-80 c C is preferred.
- the surface is treated with a heparin solution containing 1000-10000 IE heparin per litre.
- the solution contains mainly water and other suitable substances such as sodium chloride and glucose.
- the treatment time also varies here, although normally requires a treatment time 15-45 minutes. Glucose can be added to stabilise the solu tion.
- the treatment method proposed in accordance with the in ⁇ vention results in the formation of a heparin layer which, has been judged, on the tests carried out, to be some ten times better than a heparin layer produced in accordance with the present standpoint of technics. It is assumed th palladium binds to the amine group in the glucose amine part of the heparin molecule, possibly in combination with van den Waals bonds to oxygen atoms in the heparin chain and in the sulphone group which is bound to the amine gro in the glucose amine part of the molecule.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7801853 | 1978-02-17 | ||
SE7801853 | 1978-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0015909A1 true EP0015909A1 (en) | 1980-10-01 |
Family
ID=20334023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19790900219 Withdrawn EP0015909A1 (en) | 1978-02-17 | 1979-09-11 | A method of producing thrombosis-resistant surfaces |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0015909A1 (ja) |
JP (1) | JPS55500091A (ja) |
DK (1) | DK427079A (ja) |
WO (1) | WO1979000638A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU625215B2 (en) * | 1988-06-04 | 1992-07-02 | Sanofi-Aventis Deutschland Gmbh | Hirudin derivatives with delayed action |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5281662A (en) * | 1988-08-03 | 1994-01-25 | New England Deaconess Hospital Corporation | Anthraquinone dye treated materials |
US5112615A (en) * | 1988-08-03 | 1992-05-12 | New England Deaconess Hospital Corporation | Soluble hirudin conjugates |
US5167960A (en) * | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
CA2000887A1 (en) * | 1988-11-01 | 1990-05-01 | Cecilia S.L. Ku | Thromboresistant materials and methods for making same |
US5196404B1 (en) * | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
US5135516A (en) * | 1989-12-15 | 1992-08-04 | Boston Scientific Corporation | Lubricious antithrombogenic catheters, guidewires and coatings |
DE59109048D1 (de) * | 1990-02-14 | 1998-10-15 | Pentapharm Ag | Inhibitoren zur antikoagulierenden Vorbehandung von Blutproben |
AU8492991A (en) * | 1990-10-04 | 1992-04-28 | New England Deaconess Hospital Corporation | Soluble thrombogenesis inhibitor conjugates |
DK194091D0 (da) * | 1991-11-29 | 1991-11-29 | Metra Aps | Hydrofil og biokompatibel coatede overflader |
CN112043877B (zh) * | 2020-08-06 | 2022-10-14 | 苏州大学 | 一种蚕丝抗凝血管支架覆膜及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2702253A (en) * | 1950-11-01 | 1955-02-15 | Gasaccumulator Svenska Ab | Surface metallizing method |
US3549409A (en) * | 1969-04-28 | 1970-12-22 | Cordis Corp | Production of nonthrombogenic plastics |
-
1979
- 1979-02-16 WO PCT/SE1979/000035 patent/WO1979000638A1/en unknown
- 1979-02-16 JP JP50042479A patent/JPS55500091A/ja active Pending
- 1979-09-11 EP EP19790900219 patent/EP0015909A1/en not_active Withdrawn
- 1979-10-10 DK DK427079A patent/DK427079A/da not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO7900638A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU625215B2 (en) * | 1988-06-04 | 1992-07-02 | Sanofi-Aventis Deutschland Gmbh | Hirudin derivatives with delayed action |
Also Published As
Publication number | Publication date |
---|---|
JPS55500091A (ja) | 1980-02-14 |
WO1979000638A1 (en) | 1979-09-06 |
DK427079A (da) | 1979-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4152075B2 (ja) | 表面改質物質を調整する新方法 | |
JP4489297B2 (ja) | ヘパリンを含む組成物の使用方法 | |
CN109731137B (zh) | 具有生物抗污功能的白蛋白涂层的制备方法及具有生物抗污功能的材料 | |
US4871357A (en) | Ionic heparin coating | |
US7459169B2 (en) | Surface coating comprising bioactive compound | |
JPH05500314A (ja) | 改良されたイオン性ヘパリンコーティング | |
EP0015909A1 (en) | A method of producing thrombosis-resistant surfaces | |
JPH0145373B2 (ja) | ||
AU6502590A (en) | Process for the preparation of surface modified solid substrates | |
JPH0635512B2 (ja) | 表面変性された基材およびその製法 | |
US6146771A (en) | Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine | |
EP0309473B1 (en) | An article adapted for contact with blood, a process for the preparation thereof as well as uses thereof | |
Larsson et al. | The stability of glutardialdehyde-stabilized 35-heparinized surfaces in contact with blood | |
WO2003072154A1 (en) | Composition and method for coating medical devices | |
EP0231573B1 (en) | Improved ionic heparin coating | |
CA1340800C (en) | Articles exhibiting a blood-compatible surface layer and process for providing articles with such a surface layer | |
JP2001204809A (ja) | 血液適合性組成物およびそれを被覆した医療用具 | |
WO2023225749A1 (en) | Multifunctional surface modification of biomaterials with agents to reduce thrombosis | |
JPH04146766A (ja) | 抗血栓性医用材料および医用器具 | |
JP2003048840A (ja) | 抗菌性付与抗血栓性組成物およびそれをコートした医療用具 | |
JPH0777586B2 (ja) | 血液中電解質センサ用被覆材料 | |
AU2317888A (en) | Articles exhibiting a blood-compatible surface layer and process for providing articles with such a surface layer | |
NO321372B1 (no) | Anvendelse av en sammensetning som omfatter heparin for fremstilling av en ikke-trombogen overflate. | |
JPS6248630A (ja) | ヘパリン含有イオン複合体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): FR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19801227 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SOEDERVALL, BILLY, VALTER Inventor name: BERGSTROEM, AXEL, EMIL |